Results 141 to 150 of about 93,929 (247)

Targeted therapy in melanoma [PDF]

, 2009
Tawbi,
core   +1 more source

A cross sectional analysis of the association between FGF19 tumor expression and serum AFP levels in advanced HCC patients [PDF]

, 2017
PURPOSE: HCC is a complicated disease with high mortality rates and limited treatment options. No universal clinical or molecular classification established to inform better treatment options.
Clifford, Corinne
core  

Global patterns and trends in kidney cancer incidence and mortality

International Journal of Cancer, Volume 159, Issue 1, Page 67-77, 1 July 2026.
What's New? Decreasing mortality from kidney cancer in developed countries contrasts with persistently high or rising mortality in less‐developed regions. Factors underlying this widening gap remain incompletely understood. Using GLOBOCAN 2022 data, the present study examined patterns in kidney cancer incidence and mortality worldwide and the relation ...
Anton Barchuk, Jerome Vignat, Kari A. O. Tikkinen, Ahmedin Jemal, Freddie Bray, Ariana Znaor   +5 more
wiley   +1 more source

Summative Comorbidities Are Independently Associated With Mortality in Patients With Hepatocellular Carcinoma

Liver International, Volume 46, Issue 7, July 2026.
ABSTRACT Background Comorbidities might limit therapeutic options and negatively impact survival in patients with hepatocellular carcinoma (HCC). The Charlson Comorbidity Index (CCI) is widely used to summarize and quantify comorbidities. Methods HCC patients diagnosed between 1992 and 2018 at the Medical University of Vienna were retrospectively ...
Tobias Meischl, Moritz Steurer, Lorenz Balcar, Yannick Marcour, Patrick Meier, Lukas Bucher, Ye‐Rin Park, Katharina Pomej, Mattias Mandorfer, Thomas Reiberger, Michael Trauner, Bernhard Scheiner, Matthias Pinter   +12 more
wiley   +1 more source

Design and Synthesis of Pyrimidino[4,5‐d]Pyrimidine‐Based Compounds as Potent B‐RAF V600E Inhibitors

ChemMedChem, Volume 21, Issue 11, 15 June 2026.
Novel pyrimido[4,5‐d]pyrimidine‐based inhibitors selectively target B‐RAF V600E with nanomolar affinity and adopt distinct type‐II binding modes. Complementary cellular profiling reveals highly active analogs, underscoring the versatility of this chemotype and establishing it as a promising scaffold for the development of next‐generation kinase ...
Eleftheria A. Georgiou, Kalliopi Christopoulou, Amalia D. Kalampaliki, Aikaterini F. Giannopoulou, Eleftheria Chatziorfanou, Vivi Bafiti, Andreas Krämer, Athanasios Papakyriakou, Dimitrios J. Stravopodis, Stefan Knapp, Ioannis K. Kostakis   +10 more
wiley   +1 more source

Methyltransferase‐Like 14 Promotes the Angiogenesis of Hepatocellular Carcinoma via Targeting Vascular Endothelial Growth Factor A

Cancer Reports, Volume 9, Issue 6, June 2026.
ABSTRACT Background N6‐methyladenosine (m6A) modification is a pivotal epitranscriptomic regulator implicated in tumor progression. As a core component of the m6A methyltransferase complex, METTL14 is known to suppress tumorigenesis; however, its specific role in tumor angiogenesis remains elusive. Given that Vascular Endothelial Growth Factor A (VEGFA)
Xinmiao Xiong, Chuanfang Shu, Ziqun Qu, Jiayan Li, Wei Ye, Lili Wang   +5 more
wiley   +1 more source

Giant cellulitis‐like Sweet's syndrome induced by gilteritinib

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Juan de Luque‐Fernández, Irene Rivera‐Ruiz, Irene Suárez‐Vergne, Inmaculada Sánchez‐Ramírez, Manuel Galán‐Gutiérrez, Antonio José Vélez García‐Nieto   +5 more
wiley   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Network Pharmacology and Integrated Experimental Evidence Demonstrate That Ophiopogonin D Suppresses Hepatocellular Carcinoma Progression via the UCK2–SLC7A11 Axis

Food Science &Nutrition, Volume 14, Issue 6, June 2026.
Ophiopogonin D exerts anti‐HCC effects by targeting UCK2 and inducing ferroptosis via the UCK2‐SLC7A11 axis. ABSTRACT Hepatocellular carcinoma (HCC) treatment faces significant challenges, including high toxicity and drug resistance. Ophiopogonin D, the active compound derived from the medicinal food material Ophiopogon japonicus (Mai Dong), has ...
Yuxia Hao, Haris Muhammad, Yushi Wang, Yan Wang, Lu Cui, Jiajia Quan, Bing Xie, Xi Li   +7 more
wiley   +1 more source

Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Durvalumab plus tremelimumab (Dur/Tre) is the first‐line treatment for unresectable hepatocellular carcinoma (uHCC). Immune‐mediated adverse events (imAEs) are common; however, the impact of specific imAE types on treatment persistence and outcomes remains unclear.
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yoshihide Ueda, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, on behalf of the RELPEC Group and HCC 48 Group   +53 more
wiley   +1 more source